Brand Intelligence Graph
Company Overview
About Alto Neuroscience
Alto Neuroscience is a publicly-listed (Nasdaq: ANRO) clinical-stage biotech applying biomarker-stratified patient selection to psychiatry — matching patients to drugs based on brain biology rather than symptom checklists that have historically produced inconsistent treatment outcomes. The company raised a $120 million PIPE in 2026 to fund Phase 2b development of ALTO-207, a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The FDA has granted Fast Track designation for ALTO-101, and Alto has four clinical data readouts expected through 2027.
Business Model & Competitive Advantage
Treatment-resistant depression affects approximately 3 million Americans who fail two or more adequate antidepressant trials. Existing treatments for TRD (ketamine/esketamine, ECT, TMS) are effective but require clinic visits and carry significant side effect profiles. Alto's oral fixed-dose combination targeting TRD represents a potentially more accessible outpatient treatment option.
Competitive Landscape 2025–2026
The biomarker stratification approach is Alto's scientific differentiator: conventional antidepressant trials enroll unselected patients and achieve 30-40% response rates. Alto's platform uses neuroimaging, EEG, and genetic biomarkers to identify the 30-40% of patients most likely to respond to each specific drug mechanism — enabling clinical trials with higher response rates in the selected subpopulation and regulatory filings for a defined biomarker-positive indication.
Key Differentiators
Emerging Innovator
Alto Neuroscience is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Alto Neuroscience with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alto Neuroscience? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alto Neuroscience Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alto Neuroscience vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →